

Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer

Sonia Ancoli-Israel · Michelle Rissling · Ariel Neikrug · Vera Trofimenko ·
Loki Natarajan · Barbara A. Parker · Susan Lawton · Paul Desan · Lianqi Liu

Received: 3 October 2010 / Accepted: 30 May 2011 / Published online: 11 June 2011
© Springer-Verlag 2011

Abstract

Purpose Fatigue is one of the most disturbing complaints of cancer patients and is often the reason for discontinuing treatment. This randomized controlled study tested the hypothesis that increased morning bright light, compared to dim light, would result in less fatigue in women with breast cancer undergoing chemotherapy.

Methods Thirty-nine women newly diagnosed with stage I–III breast cancer were randomized to either bright white light (BWL) or dim red light (DRL) treatment and were

instructed to use the light box for 30 min every morning throughout the first four cycles of chemotherapy. The Multidimensional Fatigue Symptom Inventory was administered prior to the start of chemotherapy (baseline), during the chemotherapy treatment week of cycle 1 (C1TW), the last week (recovery week) of cycle 1 (C1RW), the chemotherapy treatment week of cycle 4 (C4TW), and the last week (recovery week) of cycle 4 (C4RW).

Results The DRL group reported increased fatigue at C1TW ($p=0.003$) and C4TW ($p<0.001$) compared to baseline, while there was no significant change from baseline in the BWL group. A secondary analysis showed that the increases in fatigue levels in the DRL group were not mediated through nor associated with changes in sleep or in circadian rhythms as measured with wrist actigraphy. **Conclusions** The results of this study suggest that morning bright light treatment may prevent overall fatigue from worsening during chemotherapy. Although our hypothesis that overall fatigue would improve with bright light treatment was not supported, the lack of deterioration in total fatigue scores suggests that bright morning light may be a useful intervention during chemotherapy for breast cancer.

Parts of this study were presented at the 2008 Annual Sleep Meetings, Baltimore, MD, USA.

This study was supported by the California Breast Cancer Research Program 11 IB-0034, a grant from Litebook, Inc., NCI CA112035, NIH M01 RR00827, P60MD00220, and The Rebecca and John Moores UCSD Cancer Center (NCI P30 CA23100).

S. Ancoli-Israel (✉) · V. Trofimenko · S. Lawton · L. Liu
Department of Psychiatry, University of California, San Diego,
9500 Gilman Drive, # 0733,
La Jolla, CA 92093-0733, USA
e-mail: sancoliisrael@ucsd.edu

S. Ancoli-Israel · M. Rissling · A. Neikrug
SDSU/UCSD Joint Doctoral Program in Clinical Psychology,
San Diego, CA, USA

L. Natarajan
Department of Family and Preventive Medicine,
University of California, San Diego,
San Diego, CA, USA

B. A. Parker
Department of Medicine, University of California, San Diego,
San Diego, CA, USA

P. Desan
Department of Psychiatry, Yale University School of Medicine,
New Haven, CT, USA

Keywords Fatigue · Breast cancer · Chemotherapy ·
Light treatment

Fatigue is one of the most frequent and most disturbing complaints of cancer patients [1]. Studies have shown that over 75% of patients undergoing radiation or chemotherapy report feeling tired or weak [2]. Fatigue interferes with daily activities, reduces quality of life [1], and is often the reason for discontinuing treatment [2]. The fatigue of cancer is different from general fatigue. Cancer-related

fatigue (CRF) has been defined as a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning [3]. CRF is characterized by feeling tired even after rest, a reduced capacity to carry out normal daily activities, slow physical recovery from tasks, diminished concentration, and is more severe and distressing than typical fatigue [4, 5].

Factors contributing to fatigue include postoperative pain, emotional distress (depression, anxiety), anemia, sleep disturbance, nutritional deficits, decreased physical fitness and activity levels, endocrine dysfunction, inflammatory cytokines, and/or disrupted circadian rhythms [6–9]. There is some evidence that the amount of fatigue might be affected by chemotherapy [10]. In our previous work, however, we found that patients were already fatigued even before they began chemotherapy and that fatigue worsened during treatment [8]. Other clinical studies have indicated that a large proportion of breast cancer patients continue to experience fatigue for months after therapy is completed [11, 12].

On the other hand, fatigue is also a common complaint in patients with other disorders, such as depression, jet lag, shift work disorder, circadian rhythm disturbances (e.g., delayed or advanced sleep phase), and sleep disorders. These disorders are commonly treated with bright light therapy [13, 14]. In addition to improving depression, sleep, and shifting circadian rhythms [13, 15–19], light is known to have an alerting effect. Phipps-Nelson et al. found that increasing bright light exposure, compared to dim light, decreased subjective sleepiness and improved performance [20]. Other investigators found similar results [21–23]. Reviews and meta-analyses have confirmed the efficacy of light treatment for these disorders [24]. Although fatigue among breast cancer patients has been found to be related to disrupted circadian rhythms [25, 26], and it is known that bright light improves circadian rhythms, the effect of light treatment on fatigue has not been investigated.

Liu et al. examined the relationship between ambient light exposure and fatigue in women with breast cancer prior to and during chemotherapy [27, 28]. Prior to chemotherapy, women were exposed to 54 min of bright light with a mean of 468 lx exposure per day. (As a point of reference, social lighting is <200 lx, a bright office <500 lx, outdoors on a cloudy day 1,500–5,000 lx, and outdoors on a sunny day 10,000 to 50,000 lx or more.) During chemotherapy, particularly during week 1 of cycle 1 and week 1 of cycle 4, the amount of time exposed to bright light was reduced to about 35 min with a mean of only 300 lx. In addition, greater fatigue was associated with lower light intensity and less time exposed to bright light [28]. This association between fatigue and light exposure may suggest the existence of a vicious cycle, with side effects of chemotherapy causing

more severe fatigue, more severe fatigue causing less outdoor activity, less time spent outdoors causing lower bright light exposure, and lower light exposure then further exacerbating the fatigue (see Fig. 1a). Increased light exposure may break this vicious cycle and mitigate the fatigue (see Fig. 1b). As many studies have shown that light treatment is more effective when administered in the morning than in the evening [29, 30], this randomized controlled study tested the hypothesis that increased morning bright light, compared to dim light exposure, would result in less fatigue during chemotherapy.

Methods

Subjects

Fifty-eight women were referred by medical oncologists in the San Diego community or from the Moores UCSD Cancer Center. All women were newly diagnosed with stage I–III breast cancer, as determined by their oncologist using the American Joint Committee on Cancer Staging Manual 6th Edition [31], and each was scheduled to receive at least four cycles of chemotherapy. As shown in Fig. 2, of the 58 women screened, 41 (71%) consented and were randomized, and 2 dropped out after randomization but before the start of light treatment. The mean age of the





Fig. 1 Model of a negative feedback loop of chemotherapy leading to fatigue, which leads to less time spent outdoors, which leads to less bright light exposure, which could lead to increased fatigue (a). We hypothesized that the addition of morning bright light would break this cycle (b)

Fig. 2 Consort diagram of participant recruitment and retention

remaining 39 women (67% of the original sample) was 53.95 years (SD=9.1, range=32–70 years).

Exclusion criteria included being pregnant, having metastatic or stage IIIB (including inflammatory) breast cancer, significant preexisting anemia or confounding underlying medical illnesses, or any other physiological or psychological impairments that would have limited participation.

The study was approved by the University of California Committee on the Protection of Human Subjects.

Procedure

Once informed consent was signed, the women were randomized, based on a randomization table, to either the

bright white light group (BWL; $n=23$) or the dim red light group (DRL; $n=16$) with a larger proportion randomized to BWL to provide a larger sample treated with this noninvasive, potentially beneficial treatment. Rather than being told that the DRL was a placebo, participants were told that “It is unclear if certain frequencies of light are better than others and so both white and red lights are being tested.”

Participants met with research staff either at their homes or at the UCSD General Clinical Research Center where questionnaires were administered prior to the start of chemotherapy (baseline, BL), during the chemotherapy treatment week of cycle 1 (C1TW), the last week (recovery week) of cycle 1 (C1RW), the chemotherapy treatment week of cycle 4 (C4TW), and the last week (recovery week) of cycle

4 (C4RW). All but two women received 3-week cycles of chemotherapy, while the two received 2-week cycles. Only data from the primary outcome of fatigue are presented.

Actigraphy

Wrist actigraphs were used to estimate sleep/wake activity and circadian rhythm data. Activity was recorded with the Actiwatch-Light® (Mini Mitter/Phillips/Respironics) for three consecutive days (i.e., 72 h) at each time point: prechemotherapy and during the treatment and recovery weeks of cycle 1 and cycle 4. The Actiwatch-Light® uses a piezoelectric linear accelerometer (sensitivity < 0.01 g force) with a sampling rate of 32 Hz to measure and record wrist movement. Calculating wrist activity over time allowed for an objective measure of duration and disruption of sleep and circadian activity rhythms. The recorded actigraphy data were analyzed using the Actiware® sleep and activity monitoring software program (version 5, by Mini Mitter/Philips/Respironics). Women kept a sleep log with bed time and up time for each of the 3 days at each time point, and the sleep log was used to edit the actigraphy data.

Light treatment

Light was administered via a Litebook 1.2 (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6 × 5 × 1 in.) and lightweight (8 oz.) box designed to be placed on a table about 18 in. from the patient's head and within 45° of the midline of the visual field. The Litebook® utilizes 60 white light-emitting diode (LED) lights with a distribution of energy particularly concentrated in the middle and long wavelengths [32]. For purposes of safety, the Litebook® emits no ultraviolet light. An identical-appearing device utilizing red LEDs emitting DRL at < 50 lx was used for the placebo group.

The appropriate light box was given to each woman. All women were instructed to place the light box on a table or countertop while seated with the distance between the eyes and the device of approximately 18 in. and to self-administer the light treatment for 30 min every morning upon awakening throughout the first four cycles of chemotherapy.

The Litebooks® used for this study were modified to include an integrated meter which allowed for compliance monitoring by recording the time and duration the light box was on each day. Partial compliance data were available for 30 patients (BWL, $n=17$; DRL, $n=13$), with some data missing for some weeks. The compliance meter failed to record usage for the remainder of the patients.

Fatigue

The Short Form of the Multidimensional Fatigue Symptom Inventory (MFSI-sf) was used to measure fatigue. The

MFSI-sf is a 30-item scale with 5 subscales: General, Physical, Emotional, and Mental Fatigue, and Vigor. Each subscale includes six items and each item is rated on a five-point scale indicating how true the statement was during the last week (0=not at all, 4=extremely). The sum of the General, Physical, Emotional, and Mental subscale scores minus the Vigor subscale score generates a total score. The range of possible score for each subscale is 0 to 24, and the range for total score is -24 to 96, with a higher score indicating more severe fatigue, except for the Vigor subscale, where larger score indicates less fatigue. The mean of the normal controls in the original validation study was 0.85 [33, 34].

Data analysis

Descriptive statistics were calculated both for the entire group and separately for each treatment group. *T* tests and Fisher's exact tests were used to assess group differences at baseline for possible confounders (i.e., demographic variables, clinical characteristics, and chemotherapy regimen). Variables that significantly differed between the treatment groups were to be controlled for in the inferential analysis; however, there were no significant differences between groups, so no confounders were controlled for.

Linear mixed-effects models and restricted maximum likelihood methods were used for comparing the progression of fatigue during chemotherapy for each group [35]. Contrasts were included in the models to compare fatigue levels during chemotherapy regimen (i.e., C1TW, C1RW, C4TW, and C4RW) to pretreatment baseline values for each treatment group.

Mixed models allow for partial data where the number of measures per person could vary and, therefore, women with missing data at some time points could be included in the analysis [35]. Mixed models rely on the "missing at random" assumption. Furthermore, mixed models decrease the chance of bias from analyzing only completing subjects.

Results

Demographics

The women were primarily Caucasian, married, with high school or some college education, and with a yearly family income of less than \$100,000 (Table 1). Their cancer history is presented in Table 2, which shows the percent of women in each stage of breast cancer, menopausal status at study entry, surgery status, and chemotherapy regimen. All but two women had chemotherapy regimens that lasted 3 weeks per cycle. There were no significant differences between randomized groups in any of these variables.

Table 1 Demographic and medical characteristics at baseline for the two randomized groups

	BWL (<i>n</i> =23)	DRL (<i>n</i> =16)
Age, mean years (SD)	54.3 (9.3)	53.5 (9.0)
Marital status, <i>n</i> (%)		
Never married	1 (4.4)	1 (6.3)
Divorced	7 (30.3)	3 (18.7)
Widowed	2 (8.7)	1 (6.3)
Married	13 (56.6)	11 (68.7)
Ethnicity/race, <i>n</i> (%)		
Caucasian	15 (65.2)	13 (81.3)
African American/Black	4 (17.4)	2 (12.4)
Asian	2 (8.7)	1 (6.3)
Other	2 (8.7)	
Education, <i>n</i> (%)		
Some high school or less	1 (4.4)	0
Completed high school	1 (4.4)	0
Some college	6 (26.1)	6 (37.5)
College degree	8 (34.7)	4 (25)
Graduate degree	7 (30.4)	6 (37.5)
Annual family income, <i>n</i> (%)		
≤\$15,000	5 (21.7)	3 (18.8)
≤\$30,000	6 (26.1)	0
≤\$50,000	1 (4.4)	2 (12.5)
≤\$100,000	4 (17.4)	2 (12.5)
>\$100,000	5 (21.7)	6 (37.4)
Did not answer	2 (8.7)	3 (18.8)

Compliance with treatment

In the BWL group, the 17 patients for whom compliance data were available used their light boxes for a mean of 32 days (mean of 46.7% of the days) for an average of 31.5 min/day (SD=9.89). In the DRL group, the 13 patients for which compliance data were available used their light boxes for a mean of 36 days (mean of 48.7% of the days) for an average of 33.92 min/day (SD=10.93). There were no significant differences in compliance between the two groups.

Fatigue—MFSI-sf total score

Figure 3 shows the levels of the total MFSI-sf scores for each group for each time point. There was no statistical difference between groups at baseline prior to the start of chemotherapy. There was a group×time interaction at C4TW ($p=0.022$), suggesting that the change from baseline in the DRL group was significantly different than the change in the BWL group. The DRL group fatigue scores significantly increased 11.7 points from baseline to C1TW ($p=0.003$) and 22.2 points from baseline to C4TW ($p<0.001$). There were no

significant changes from baseline to recovery weeks in cycle 1 or cycle 4 in the DRL group. On the other hand, the fatigue scores for the BWL group did not significantly change at any time point compared to baseline.

A secondary mixed-model analysis was conducted to examine whether these changes in fatigue levels were associated with concomitant changes in sleep or circadian activity rhythms. The results indicated that the changes in fatigue were not significantly associated with changes in sleep or in circadian rhythms, and hence, the effect of light treatment on fatigue was not mediated through either of these other variables.

Fatigue—MFSI-sf subscales

Analyses were conducted on the MFSI-sf subscales, showing different results for the different subscales. Table 3 shows the means and standard errors for each group for each subscale.

There were no group×time interactions for the general, physical, or mental subscales. On the general MFSI-sf subscale, both groups had worse scores compared to baseline during C1TW (BWL, $p=0.033$; DRL, $p=0.0006$) and during C4TW (BWL, $p=0.002$; DRL, $p<0.0001$). There was a similar pattern on the physical subscale, with both groups again having worse scores compared to baseline during C1TW (BWL, $p=0.035$; DRL, $p=0.026$) and C4TW (BWL, $p=0.048$; DRL, $p=0.0008$). On the mental subscale, the two groups showed a decrement compared to baseline but at different time points, with the BWL group showing a decrement during C4RW ($p=0.0019$) and the DRL showing a decrement during C4TW ($p=0.022$).

However, on the emotional subscale, there was a group effect ($p=0.014$), indicating that the groups differed at baseline, and a group×time effect ($p=0.03$), suggesting that the change in emotional subscale scores from baseline in the BWL group was significantly different than the change in the DRL group. The BWL showed an improvement compared to baseline during C1RW ($p=0.006$), C4TW ($p=0.053$), and C4RW ($p=0.058$), while there were no significant changes in the DRL group.

There were no significant changes in the BWL group and no group×time interaction on the vigor subscale; however, the DRL group showed decreased vigor compared to baseline during C1TW ($p=0.0092$) and C4TW ($p=0.0135$).

Adverse effects

There were no adverse effects reported in either the BWL or DRL group. Three women, all in the BWL group, dropped out of the study (one during C1TW and two at the end of C1TW) because they found the light uncomfortable.

Table 2 Cancer history at baseline for the two randomized groups, *n* (%)

	BWL (<i>n</i> =23)	DRL (<i>n</i> =16)
Menopausal status prechemotherapy		
Premenopausal	5 (21.7)	4 (25.0)
Perimenopausal	3 (13.0)	2 (12.5)
Postmenopausal	8 (34.8)	7 (43.8)
Posthysterectomy	6 (26.1)	3 (18.8)
Unknown	1 (4.4)	0
Cancer stage		
Stage I	4 (17.4)	5 (31.3)
Stage II	10 (43.5)	6 (37.5)
Stage III	4 (17.4)	2 (12.5)
Unknown	5 (21.7)	3 (18.7)
Surgery per chemotherapy		
Lumpectomy	7 (30.4)	8 (50.0)
Mastectomy	9 (39.1)	6 (37.5)
Double mastectomy	4 (17.4)	1 (6.3)
Preoperative chemotherapy	2 (8.7)	1 (6.3)
Unknown	1 (4.4)	0
Chemotherapy regimen		
Exactly 4 cycles of AC	3 (13.0)	3 (18.8)
Exactly 4 cycles of AC+taxotere	5 (21.7)	0
Exactly 4 cycles of AC+taxol	6 (26.1)	2 (12.5)
6 cycles of TAC	2 (8.7)	4 (25.0)
Other regimen	7 (30.4)	7 (43.7)
Prior use of hormone replacement therapy		
Yes	2 (8.7)	4 (25.0)
No	13 (56.5)	10 (62.5)
Unknown	8 (34.8)	2 (12.5)

Discussion

The results of this study suggest that morning bright light treatment may prevent overall fatigue from worsening during chemotherapy. Although our hypothesis that overall fatigue

would improve with bright light treatment was not supported, the lack of deterioration in total fatigue scores is very encouraging. Women with breast cancer experience increasing fatigue during chemotherapy. Minimizing an increase in fatigue could have a substantial positive impact on these women.




Fig. 3 MFSI-sf total fatigue scores for the BWL treatment group and the DRL treatment group at five time points (*BL* prechemotherapy baseline, *C1TW* cycle 1 chemotherapy treatment week, *C1RW* cycle 1 recovery week, *C4TW* cycle 4 chemotherapy treatment week, *C4RW* cycle 4 recovery week). There was a group×time interaction at C4TW

(*p*=0.022), suggesting that the change from baseline in the DRL group was significantly different than the change in the BWL group. The DRL group reported increased fatigue at C1TW (*p*=0.003) and C4TW (*p*<0.001) compared to baseline, while there was no significant change from baseline in the BWL group

Table 3 Means (standard errors) for MFSI-sf subscales

	Baseline	Cycle 1 treatment week	Cycle 1 recovery week	Cycle 4 treatment week	Cycle 4 recovery week
General					
BWL	6.59 (1.67)	9.59 (2.00)	8.06 (1.52)	10.69 (1.66)	7.6 (1.26)
DRL	4.44 (1.12)	9.50 (1.94)	7.46 (1.73)	13.71 (1.94)	6.64 (1.79)
Physical					
BWL	3.09 (0.83)	5.59 (1.54)	4.61(1.34)	5.13 (1.15)	3.33 (1.12)
DRL	2.25 (0.78)	4.93 (1.35)	2.15 (0.82)	6.43 (1.75)	3.21 (1.03)
Mental					
BWL	4.68 (1.23)	5.76 (1.75)	5.28 (1.53)	6.31 (1.11)	7.20 (1.49)
DRL	2.75 (0.65)	3.57 (1.12)	3.00 (1.06)	6.14 (1.61)	4.07 (1.28)
Emotional					
BWL	6.59 (1.48)	5.47 (1.26)	4.06 (1.37)	4.56 (1.19)	3.80 (0.86)
DRL	3.06 (0.75)	3.42 (1.33)	2.47 (0.81)	5.00 (1.50)	2.43 (0.77)
Vigor					
BWL	12.73 (1.16)	10.29 (1.38)	13.28 (1.12)	11.44 (1.54)	12.73 (1.36)
DRL	13.06 (1.15)	10.21 (1.70)	12.92 (1.85)	9.64 (1.95)	13.07 (2.03)

Lower scores are better, except for vigor, where higher scores are better. See text for significance levels

Analyses of the subscales showed that the group receiving BWL showed improvement on the emotional subscale, while the DRL group showed no change, and the DRL group had less vigor, while the BWL group reported no change compared to baseline. Both groups showed deterioration on the general, physical, and mental subscales.

The mechanism by which light is related to fatigue is not clear. Analyses examining whether changes in fatigue were related to changes in sleep or in circadian rhythms, as measured by wrist actigraphy, showed no such association so it is likely that changes in fatigue were not mediated through these other factors. However, it is also possible that statistical power was insufficient to demonstrate any relationship. It is also possible that the addition of morning bright light broke the cycle of low light levels contributing to increased fatigue (Fig. 1a, b). But whether it was the alerting effect of light or some other mechanism that led to the lack of deterioration of fatigue cannot be determined from this study.

Although the mechanism is unclear, other investigators have also found light therapy to be alerting and alertness could be construed to be the opposite of fatigue. Daurat et al. [23] found that bright light vs. dim light counteracted the effects of sleep deprivation on alertness and performance. In a study of simulated shift work, increased bright light exposure was associated with an amelioration of sleepiness and increased alertness [36]. Campbell et al. [37], in a consensus report on the alerting and activating effects of bright light, concluded that data from studies of bright light support the notion that bright light is associated with reports of alertness as well as with objective physiological measures.

To date, few behavioral treatments have been tested in cancer. One small study found that progressive muscle relaxation training improved sleep quality (measured with questionnaire) and CRF in women with breast cancer undergoing adjuvant chemotherapy compared to no treatment [38]. The one behavioral treatment most studied, however, has been exercise [39–42]. In 1 meta-analysis of 44 studies of survivors of various cancers, exercise was effective in reducing CRF, particularly when the exercise was of moderate intensity and in older cancer survivors [40]. In another meta-analysis of 18 studies (12 in breast cancer), Velthuis et al. [42] found that, during breast cancer treatment, home-based exercise programs showed no significant reductions in fatigue, while supervised aerobic programs resulted in a medium and significant reduction compared to no exercise. Adherence ranged from 39% of the patients in the supervised programs to 100% completion of a home-based walking program. Adverse events were reported in 67% of the studies. While the adherence rate was better in the home-based exercise program than in our light study, there was no effect on CRF and there were more adverse events reported. In addition, none of the exercise studies controlled for the amount of light exposure, although many took place outdoors and so the amount of contribution of light vs. exercise is yet to be determined. Studies are needed to determine if increased light combined with increased exercise might lead to the most effective treatment of CRF.

There were some limitations to this study. The sample size was small; yet even with the small sample size, our data support lack of worsening of fatigue and a protective

effect of bright light therapy. While the compliance with treatment did not differ between groups and most women used their light box for the full 30 min, use was only for about half of the days. We know of no other study that measured compliance to light treatment, so we cannot estimate if this compliance was better or worse than studies in other disorders. Nevertheless, even with partial compliance, BWL helped protect these women from increased fatigue. In this study, light was administered in the morning, as for most other conditions, morning light is most effective. Future studies might compare the effect of morning vs. evening light on fatigue. Future studies should also examine the effect of bright light on fatigue in other cancer patients.

In summary, fatigue is a major complaint in women with breast cancer undergoing chemotherapy. There is no standard treatment for fatigue and so women suffer from this debilitating symptom, often discontinuing their chemotherapy treatment. Oncologists may want to counsel their breast cancer patients to increase their light exposure by either spending more time outdoors in the morning hours or by using a bright light box. Morning bright light is an easy, noninvasive, nonharmful behavioral treatment that may prevent worsening of fatigue in women with breast cancer.

Acknowledgement The authors would like to thank Sherella Johnson, Feng He, and Lee Cohen for their help with aspects of the study, the participants who volunteered their time, and Drs. Andrew Hampshire, Peter Reissman, and William Stanton of Internal Medicine Associates, Dr. Sabina Wallach of Scripps/Ximed Medical Group, Hillcrest Internal Medicine, Inc., the Moores UCSD Cancer Center, Oncology Associates of San Diego, Pacific Oncology and Hematology Group, San Diego Pacific Oncology & Hematology Associates for helping in the recruitment by informing their patients about the research protocol.

References

- Richardson A (1995) Fatigue in cancer patients: a review of the literature. *European J Cancer Care* 4:20–32
- Winningham ML, Nail LM, Burke MB, Brophy L, Cimprich B, Jones LS, Pickard-Holley S, Rhodes V, St Pierre B, Beck S, Glass EC, Mock VL, Mooney KH, Piper B (1994) Fatigue and the cancer experience; the state of the knowledge. *Oncol Nurs Forum* 21:23–36
- National Comprehensive Cancer Network (2008) Cancer-related fatigue: NCCN clinical practice guidelines in oncology. NCCN, Fort Washington, PA
- Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S (2003) Cancer-related fatigue: evolving concepts in evaluation and treatment. *Cancer* 98:1786–1801
- Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C (2000) NCCN Practice Guidelines for Cancer-Related Fatigue. *Oncology (WillistonPark)* 14:151–161
- Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR (2008) Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. *J Clin Oncol* 26:971–982
- Mills PJ, Parker BA, Dimsdale JE, Sadler GR, Ancoli-Israel S (2005) The relationship between fatigue, quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. *Biol Psychol* 69:85–96
- Ancoli-Israel S, Liu L, Marler M, Parker BA, Jones V, Robins Sadler G, Dimsdale JE, Cohen-Zion M, Fiorentino L (2006) Fatigue, sleep and circadian rhythms prior to chemotherapy for breast cancer. *Support Care Cancer* 14:201–209
- Liu L, Fiorentino L, Natarajan L, Parker BA, Mills PJ, Sadler GR, Dimsdale JE, Rissling M, He F, Ancoli-Israel S (2009) Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. *Psycho-Oncology* 18:187–194
- Haes JD, Raategever J, Van der Berg M, Hamersma E, Neijt J (1987) Evaluation of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy. In: Aaronson N, Beckmann J (eds) *Quality of life of cancer patients*. Raven, New York, pp 215–226
- Ganz P, Coscarelli A, Fred C et al (1996) Breast cancer survivors: psychosocial concerns and quality of life. *Breast Cancer Res Treat* 38:183–199
- Ganz PA, Kwan L, Stanton AL, Bower JE, Belin TR (2011) Physical and psychosocial recovery in the year after primary treatment of breast cancer. *J Clin Oncol* 29:1101–1109
- Golden RN, Gaynes BN, Ekstrom RD (2005) The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. *Am J Psychiatry* 162:656–662
- Chesson A, Littner M, Davila DG, Anderson WM, Grigg-Damberger M, Hartse KM, Johnson S, Wise M (1999) Practice parameters for the use of light therapy in the treatment of sleep disorders. *Sleep* 22:641–660
- Ancoli-Israel S, Martin JL, Kripke DF, Marler M, Klauber MR (2002) Effect of light treatment on sleep and circadian rhythms in demented nursing home patients. *J Am Geriatr Soc* 50:282–289
- Boulos Z, Campbell SS, Lewy AJ, Terman M, Dijk DJ, Eastman CI (1995) Light treatment for sleep disorders: consensus report. VII. Jet lag. *J Biol Rhythm* 10:167–176
- Eastman CI, Boulos Z, Terman M, Campbell SS, Dijk DJ, Lewy AJ (1995) Light treatment for sleep disorders: consensus report. VI. Shift work. *J Biol Rhythm* 10:157–164
- Klerman EB, Duffy JF, Dijk DJ, Czeisler CA (2001) Circadian phase resetting in older people by ocular bright light exposure. *J Investig Med* 49:30–40
- Lack L, Wright H, Kemp K, Gibbon S (2005) The treatment of early-morning awakening insomnia with 2 evenings of bright light. *Sleep* 28:616–623
- Phipps-Nelson J, Redman JR, Dijk DJ, Rajaratnam SM (2003) Daytime exposure to bright light, as compared to dim light, decreases sleepiness and improves psychomotor vigilance performance. *Sleep* 26:695–700
- Lafrance C, Dumont M, Lesperance P, Lambert C (1998) Daytime vigilance after morning bright light exposure in volunteers subjected to sleep restriction. *Physiol Behav* 63:803–810
- Akerstedt T, Landstrom U, Bystrom M, Nordstrom B, Wibom R (2003) Bright light as a sleepiness prophylactic: a laboratory study of subjective ratings and EEG. *Percept Mot Ski* 97:811–819
- Daurat A, Aguirre A, Foret J, Gonnet P, Keromes A, Benoit O (1993) Bright light affects alertness and performance rhythms during a 24-h constant routine. *Physiol Behav* 53:929–936
- Terman M, Terman JS, Quitkin FM, McGrath PJ, Stewart JW, Rafferty B (1989) Light therapy for seasonal affective disorder: a review of efficacy. *Neuropsychopharmacology* 2(1):1–22

25. Berger AM, Farr L (1999) The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. *Oncol Nurs Forum* 26:1663–1671
26. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Matteson S, Rakita D, Andrews PLR (2002) Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. *Support Care Cancer* 10:329–336
27. Liu L, Johnson SS, Fiorentino L, Parker BA, Sadler GR, Cohen-Zion M, Marler M, Ancoli-Israel S (2004) Light exposure and reported sleep, mood, functional performance and quality of life in breast cancer. *Sleep* 27:A323
28. Liu L, Marler M, Parker BA, Jones V, Johnson S, Cohen-Zion M, Fiorentino L, Sadler GR, Ancoli-Israel S (2005) The relationship between fatigue and light exposure during chemotherapy. *Support Care Cancer* 13:1010–1017
29. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas K, Blood ML, Jackson JM (1998) Morning vs evening light treatment of patients with winter depression. *Arch Gen Psychiat* 55:875–882
30. Terman M, Terman JS, Ross DC (1998) A controlled trial of timed bright light and negative air ionization for treatment of winter depression. *Arch Gen Psychiat* 55:875–882
31. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (2002) *AJCC cancer staging manual*, 6th edn. Springer, New York
32. Desan PH, Weinstein AJ, Michalak EE, Tam EM, Meesters Y, Ruiters MJ, Horn E, Telner J, Iskandar H, Boivin DB, Lam RW (2007) A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD). *BMC Psychiatry* 7:38
33. Stein KD, Martin SC, Hann DM, Jacobsen PB (1998) A multidimensional measure of fatigue for use with cancer patients. *Cancer Prac* 6:143–152
34. Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. *J Pain Symptom Manage* 27:14–23
35. Diggle PJ, Liang KY, Zeger SL (1996) *Analysis of longitudinal data*. Oxford University Press, Oxford, pp 1–254
36. Dawson D, Campbell SS (1991) Timed exposure to bright light improves sleep and alertness during simulated night shifts. *Sleep* 14(6):511–516
37. Campbell SS, Dijk DJ, Boulos Z, Eastman CI, Lewy AJ, Terman M (1995) Light treatment for sleep disorders: consensus report. III. Alerting and activating effects. *J Biol Rhythm* 10:129–132
38. Demiralp M, Oflaz F, Komurcu S (2010) Effects of relaxation training on sleep quality and fatigue in patients with breast cancer undergoing adjuvant chemotherapy. *J Clin Nurs* 19:1073–1083
39. Litterini AJ, Jette DU (2011) Exercise for managing cancer-related fatigue. *Phys Ther* 91:301–304
40. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA, Johnson BT (2011) Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 20:123–133
41. Brem S, Kumar NB (2011) Management of treatment-related symptoms in patients with breast cancer. *Clin J Oncol Nurs* 15:63–71
42. Velthuis MJ, Gasi-Idenburg SC, Aufdemkampe G, Wittink HM (2010) The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. *Clin Oncol (RCollRadiol)* 22:208–221